Received Oct 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late second dose/ First dose of Shingrix was given on 2021 and 2nd dose given on 25-SEP-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in 2021). On 25-SEP-2025, the patient received the 2nd dose of Shingrix. On 25-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose/ First dose of Shingrix was given on 2021 and 2nd dose given on 25-SEP-2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 25-SEP-2025 Pharmacist reported that he/she called patient before, about a year, a year and a half, he had not started over but now it had been four years. So, the reporter wanted to know do the patient need to re-start from scratch and receive two vaccines or do they still need one to finish. The batch number was not provided upon follow- up with the reporter.